^
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pemetrexed
Sensitive: A1 - Approval
FDA - 3 days - (New A1)
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
FDA - 3 days - (New A1)
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A1 - Approval
FDA - 3 days - (New A1)
No biomarker
NSCLC
nivolumab
Sensitive: A1 - Approval
N Engl J Med - 3 days - (New B)
PD-L1 expression
NSCLC
atezolizumab
Sensitive: A1 - Approval
Chugai Press Release - 3 days - (New A1)
ALK positive
NSCLC
alectinib
Sensitive: A1 - Approval
Cancer Med - 3 days - (New C3)
EGFR exon 20 insertion
NSCLC
Angiogenesis inhibitor
Sensitive: C3 – Early Trials
Cancer Med - 5 days - (New C3)
ALK positive
NSCLC
lorlatinib
Sensitive: A1 - Approval
J Clin Oncol - 6 days - (New B)
PD-L1 expression
NSCLC
dostarlimab
Sensitive: C2 – Inclusion Criteria
Clin Lung Cancer - 6 days - (New C3)
EGFR mutation
NSCLC
EGFR inhibitor + Angiogenesis inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 6 days - (New C3)
No biomarker
NSCLC
sugemalimab
Sensitive: A1 - Approval
CStone Pharma Press Release - 1 week - (New B)
CD276 underexpression + EGFR mutation
LUAD
EGFR inhibitor
Sensitive: C3 – Early Trials
World J Surg Oncol - 1 week - (New C3)
EML4-ALK fusion
NSCLC
alectinib
Sensitive: C3 – Early Trials
Int J Cancer - 1 week - (New C3)
EGFR mutation + RET fusion
NSCLC
osimertinib + pralsetinib
Sensitive: C3 – Early Trials
JTO Clin Res Rep - 1 week - (New C3)
EML4-ALK fusion + TP53 mutation
NSCLC
alectinib
Resistant: C3 – Early Trials
Int J Cancer - 1 week - (New C3)
SLC12A2-ROS1 fusion
NSCLC
crizotinib
Sensitive: C4 – Case Studies
SAGE Open Med Case Rep - 1 week - (New C4)
EGFR V786M
LUAD
EGFR inhibitor
Sensitive: C4 – Case Studies
Front Oncol - 1 week - (New C4)
LMO7-ALK rearrangement
LUAD
crizotinib
Sensitive: C4 – Case Studies
Front Oncol - 1 week - (New C4)
PD-L1 overexpression
NSCLC
pembrolizumab
Sensitive: A2 - Guideline
Int J Clin Oncol - 2 weeks - (New C3)
KRAS G12C
NSCLC
Immunotherapy
Sensitive: B - Late Trials
Oncotarget - 2 weeks - (New C3)
PD-L1 overexpression
NSCLC
atezolizumab + RG6058
Sensitive: B - Late Trials
Roche Press Release - 2 weeks - (New B)
ROS1 positive
NSCLC
TPX-0005
Sensitive: B - Late Trials
Turning Point Therapeutics Press Release - 2 weeks - (New B)
PD-L1 expression
NSCLC
durvalumab
Sensitive: A1 - Approval
Precision Oncology News - 2 weeks - (New A2)
PD-L1 expression
NSCLC
atezolizumab + RG6058
Sensitive: C2 – Inclusion Criteria
Lancet Oncol - 2 weeks - (New C3)
ALK positive
NSCLC
ALK1 inhibitor
Sensitive: C3 – Early Trials
Thorac Cancer - 2 weeks - (New C3)
BRAF V600E + BRAF K601_W604del
NSCLC
trametinib + dabrafenib
Sensitive: C4 – Case Studies
Cancer Genet - 2 weeks - (New C4)
KRAS G12C
NSCLC
selinexor + MRTX1257
Sensitive: D – Preclinical
Cancer Res Commun - 2 weeks - (New D)
KRAS G12C
NSCLC
sotorasib + selinexor
Sensitive: D – Preclinical
Cancer Res Commun - 2 weeks - (New D)
EGFR T790M
NSCLC
osimertinib
Sensitive: A1 - Approval
ecancer - 3 weeks - (New C3)
EGFR T790M
NSCLC
bevacizumab + osimertinib
Sensitive: C2 – Inclusion Criteria
Clin Drug Investig - 3 weeks - (New C3)
EGFR mutation
NSCLC
aumolertinib
Sensitive: C2 – Inclusion Criteria
J Exp Clin Cancer Res - 3 weeks - (New D)
PD-L1 underexpression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Clin Exp Immunol - 3 weeks - (New C3)
MET mutation
NSCLC
Immunotherapy
Resistant: C3 – Early Trials
Thorac Cancer - 3 weeks - (New C3)
SMARCA4 deletion
NSCLC
PD-L1 inhibitor
Resistant: C3 – Early Trials
Lung Cancer - 3 weeks - (New C3)
EGFR T790M
LUAD
EGFR inhibitor
Sensitive: C3 – Early Trials
PLoS One - 3 weeks - (New C3)
MYC overexpression
NSCLC
ROS1 inhibitor
Resistant: D – Preclinical
Mol Cancer Res - 3 weeks - (New D)
ROR1 positive
NSCLC
LYL797
Sensitive: D – Preclinical
ASGCT 2022 - 3 weeks - (New D)
EGFR mutation+ IDH1 R132H
NSCLC
erlotinib + AGI-5198
Sensitive: D – Preclinical
Cancer Med - 3 weeks - (New D)
EGFR exon 19 deletion
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
osimertinib
Sensitive: A1 - Approval
No biomarker
NSCLC
ramucirumab
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
gefitinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
afatinib
Sensitive: A1 - Approval
No biomarker
NSCLC
durvalumab
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ALK fusion
NSCLC
brigatinib
Sensitive: A1 - Approval
KRAS G12C
NSCLC
sotorasib
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
osimertinib
Sensitive: A1 - Approval
ALK positive
NSCLC
brigatinib
Sensitive: A1 - Approval
ROS1 fusion
NSCLC
entrectinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
tepotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
bevacizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
dacomitinib
Sensitive: A1 - Approval
EGFR T790M
NSCLC
lazertinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
dacomitinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
capmatinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
cemiplimab
Sensitive: A1 - Approval
RET fusion
NSCLC
pralsetinib
Sensitive: A1 - Approval
No biomarker
NSCLC
cisplatin + pemetrexed
Sensitive: A1 - Approval
EGFR mutation
NSCLC
gefitinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
gefitinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
ALK positive
NSCLC
crizotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ROS1 positive
NSCLC
crizotinib
Sensitive: A1 - Approval
RET fusion
NSCLC
selpercatinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 20 insertion
NSCLC
mobocertinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
erlotinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
atezolizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
tislelizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
DP
Sensitive: A1 - Approval
ALK positive
NSCLC
ensartinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
savolitinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
dacomitinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
erlotinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
EGFR mutation
NSCLC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
pemetrexed
Sensitive: A1 - Approval
No biomarker
NSCLC
carboplatin + albumin-bound paclitaxel
Sensitive: A1 - Approval
No biomarker
LUAD
nintedanib
Sensitive: A1 - Approval
EGFR expression
Lung Non-Small Cell Squamous Cancer
necitumumab
Sensitive: A1 - Approval
ALK positive
NSCLC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
BRAF V600E
NSCLC
trametinib + dabrafenib
Sensitive: A1 - Approval
EGFR exon 20 insertion
NSCLC
amivantamab-vmjw
Sensitive: A1 - Approval
No biomarker
NSCLC
docetaxel
Sensitive: A1 - Approval
No biomarker
NSCLC
erlotinib
Sensitive: A1 - Approval
ALK positive
NSCLC
ceritinib
Sensitive: A1 - Approval
No biomarker
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR T790M
NSCLC
aumolertinib
Sensitive: A1 - Approval
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + erlotinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
sintilimab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
erlotinib + ramucirumab
Sensitive: A1 - Approval
No biomarker
NSCLC
erlotinib + Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
NSCLC
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
ALK mutation
NSCLC
pembrolizumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
erlotinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
erlotinib + ramucirumab
Sensitive: A1 - Approval
ROS1 positive
NSCLC
entrectinib
Sensitive: A1 - Approval
BRAF V600
NSCLC
trametinib + dabrafenib
Sensitive: A1 - Approval
ALK positive
NSCLC
atezolizumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
atezolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
afatinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
tislelizumab
Sensitive: A1 - Approval
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
NSCLC
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
NSCLC
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
cemiplimab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
sintilimab
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
EGFR mutation
NSCLC
nivolumab + ipilimumab
Sensitive: A2 - Guideline
EGFR mutation + ALK negative + TMB-H
NSCLC
nivolumab + ipilimumab
Sensitive: A2 - Guideline
ROS1 fusion
NSCLC
crizotinib
Sensitive: A2 - Guideline
BRAF V600E
NSCLC
dabrafenib
Sensitive: A2 - Guideline
ROS1 rearrangement
NSCLC
ceritinib
Sensitive: A2 - Guideline
ROS1 rearrangement
NSCLC
crizotinib
Sensitive: A2 - Guideline
ALK rearrangement
NSCLC
crizotinib
Sensitive: A2 - Guideline
ALK rearrangement
NSCLC
alectinib
Sensitive: A2 - Guideline
ROS1 positive
NSCLC
lorlatinib
Sensitive: A2 - Guideline
EGFR mutation
NSCLC
osimertinib
Sensitive: A2 - Guideline
ALK rearrangement
NSCLC
ALK inhibitor
Sensitive: A2 - Guideline